The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The…
Initial results of the COMPETE phase 3 clinical trial—the first study to compare targeted radioligand therapy with molecular targeted therapy…
On February 26, the second edition of the Computational Oncology Master Thesis Awards took place, organized by VHIO with the aim of…
The MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance,…
Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…
The second Joint Action of the EU on Networks of Expertise on Cancer (JANE-2) officially launched on January 28-29, 2025,…
The Paseíco de la Mama solidarity initiative has enabled VHIO’s Breast Cancer Group to carry out numerous research projects over…
Published in the journal Nature Communications*, results from a first-in-human, phase I clinical trial of an oral, potent and reversible…
Dr. Raquel Pérez-Lopez, head of the Radiomics Group at VHIO and coordinator of the Oncology Commission of the Spanish Society…
Published in Cell Reports Medicine*, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation…
Presented today at the ASCO Gastrointestinal Cancers Symposium, 23-25 January in San Francisco, results of 2 phase 3 clinical studies…
The European Commission has approved dostarlimab in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary…
